News &amp; Updates

Implementing a clinical pharmacist-led service program has led to the standardization and streamlining of refractory chemotherapy-induced nausea and vomiting (CINV) management in adult haematology and oncology clinics, reports a study.

SGLT2 inhibitors help prevent new-onset AF in diabetic Asians

Use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) may reduce the risk of new-onset atrial fibrillation (AF) relative to glucagon-like peptide-1 receptor agonists (GLP-1RAs) in Asian patients with type 2 diabetes mellitus (T2DM) in a real-world practice, reports a recent study.

18 Sep 2022

Vitamin C infusion in ICU-admitted patients: Any benefit?

18 Sep 2022 by

The administration of intravenous vitamin C to patients with sepsis admitted to the intensive care unit (ICU) did not result in a reduced risk of death or organ dysfunction, according to results of the phase III LOVIT* trial.

AF patients with high comorbidity may benefit from early rhythm control

Early rhythm control (ERC) appears to cut the risk of adverse cardiovascular outcomes in atrial fibrillation (AF) patients with a CHA2DS2-VASc score of ≥4, a study has found.

Eribulin less effective in real-world HER2-negative metastatic breast cancer than in trials

The real-world effectiveness of eribulin in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer is lower than that seen in clinical trials, reveals a study.

Poststroke statin treatment confers survival benefits for cancer patients

Statin treatment following ischaemic stroke appears to extend its benefits to improved survival in patients who also have had cancer, a study has found.

16 Sep 2022

Adalimumab biosimilar performs well in chronic plaque psoriasis treatment

The adalimumab biosimilar BI 695501 has demonstrated equivalent pharmacokinetics to the reference product, with highly comparable efficacy, immunogenicity, and safety in patients with chronic plaque psoriasis, according to data from the phase III VOLTAIRE-X trial.

16 Sep 2022

Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection

16 Sep 2022 by

Treatment with vebicorvir (VBR) plus nucleos(t)ide reverse transcriptase inhibitors (NrtIs) among virologically suppressed patients with chronic hepatitis B virus (HBV) is well tolerated and has a favourable safety profile, according to a 24-week study.

16 Sep 2022

5-fluorouracil not superior to imiquimod in long-term cSCC prevention

Despite prior evidence of excellent actinic keratosis (AK) destruction efficacy, 5-fluorouracil (5-FU) does not appear to be better than imiquimod in the prevention of cutaneous squamous cell carcinoma (cSCC), reports a recent study.

Hypophosphatemia events more frequent with ferric carboxymaltose vs ferric derisomaltose